KYMERA THERAPEUTICS INC
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 187
- Market Cap
- $3.1B
- Website
- http://www.kymeratx.com
Clinical Trials
7
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)
- First Posted Date
- 2025-04-25
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Kymera Therapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06945458
- Locations
- 🇺🇸
Kymera Investigative Site, San Antonio, Texas, United States
First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Kymera Therapeutics, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06673667
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors
- Conditions
- Acute Lymphocytic LeukemiaMyeloid MalignanciesLymphomasAdvanced Solid Tumors
- Interventions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Kymera Therapeutics, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT05775406
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL
- Conditions
- Diffuse Large B Cell LymphomaDLBCLMYD88 Gene MutationNon Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Kymera Therapeutics, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT05233033
- Locations
- 🇺🇸
MedStar Georgetown University Hospital, Washington, D.C., District of Columbia, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients with Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors
- Conditions
- Non Hodgkin Lymphoma (NHL)T-cell Prolymphocytic Leukemia (T-PLL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-Cell Lymphoma (CTCL)Large Granular Lymphocytic Leukemia (LGL-L)Solid Tumors
- Interventions
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Kymera Therapeutics, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT05225584
- Locations
- 🇺🇸
UC Irvine Health-Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
- Prev
- 1
- 2
- Next